WuXi Biologics will build a dedicated vaccine manufacturing facility as part of a partnership with an unnamed “global vaccine leader”.
The company’s joint venture with Shanghai Hile Bio-technology, WuXi Vaccines, has signed a 20-year manufacturing contract with the aforementioned leader valued at $3 billion.
As part of that agreement, the company will build a facility dedicated to manufacture one of its partner’s vaccine products for the global market.
The facility will include drug substance manufacturing, drug product manufacturing, manufacture science and technology labs, as well as quality control labs.
“Vaccine CDMO is one of the next growth areas for WuXi Biologics. Once this project is initiated, our vaccine business will contribute substantially to the growth of WuXi Biologics,” said Dr. Chris Chen, CEO of WuXi Biologics and Chairman of WuXi Vaccines.